@article{d635dc1a88ab4202b7d6729ea35b3b0d,
title = "Extended safety studies of the attenuated live tuberculosis vaccine SO2 based on phoP mutant",
abstract = "Safety is one of the main concerns for attenuated live vaccine candidates. Here we extend the stability and attenuation studies of the promising tuberculosis vaccine candidate based on Mycobacterium tuberculosis phoP mutant strain, SO2. Stability of the phoP mutation was tested after sub-culturing SO2 strain for 6 months in laboratory media and also after 3 months of infection in SCID mice. Results showed no reversion of the phoP mutation either in vitro or in vivo. In addition, SO2 was fully sensitive to four major first-line antituberculous drugs against tuberculosis. Safety and toxicity studies were performed in guinea pigs. Animals were infected with a quantity of SO2 equivalent to 50 vaccination doses (2.5 × 106 CFUs) and weight was monitored for 6 months. All animals survived and no histological lesions were found, showing full attenuation of SO2. Studies in a post-exposure model of guinea pigs and mice, previously infected with M. tuberculosis, were performed and no toxicity effects were found after inoculation of SO2. All these results together confirm that SO2 has a secure safety profile that encourages its use in clinical trials.",
keywords = "Attenuated vaccines, BCG, Safety",
author = "Cardona, \{P. J.\} and Asensio, \{J. Gonzalo\} and A. Arbu{\'e}s and I. Otal and C. Lafoz and O. Gil and N. Caceres and V. Ausina and B. Gicquel and C. Martin",
note = "Funding Information: This work has been partially presented in Keystone meeting, Tuberculosis: From lab research to field trials (Vancouver 2007) and in the Third TB Vaccines for the world (CDC Atlanta 2008). The authors would like to thank the members of their groups particularly, Alberto Cebollada for the statistical analysis, Bego{\~n}a Gracia-Diaz for sensitivity assay and Dessi Marinova for the critical reading of the manuscript. This work was supported by from the Ministerio de Ciencia e Innovaci{\'o}n, BIO2005-07949-C02-01 and BIO2008-01561, FPI grant (ref. BES-2003-1088), and by the European Project, {\textquoteleft}An integrated project for the design and testing of vaccine candidates against tuberculosis: identification development and clinical studies{\textquoteright} (contract no. LSHP-CT-2003-503367). Members of the Product Developing Team of TB-VAC (G. Thiry, B. Walker, Mei Mei Ho, M. Roumiantzeff, Juhani Eskola) are gratefully acknowledged by helpful discussions encouraging moving live tuberculosis vaccines to clinical trials.",
year = "2009",
month = apr,
day = "21",
doi = "10.1016/j.vaccine.2009.02.060",
language = "English",
volume = "27",
pages = "2499--2505",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "18",
}